Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) saw its stock touch a 52-week low of $518.68 as the biotech firm contends with heightened market volatility and shifting investor sentiment.

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron Pharmaceuticals’ Debt total was $2.7 Billion at the conclusion of the most recent quarter, while its market capitalization is $52 Billion (as of 5/30/2025).

The overall negative market sentiment contributed to Regeneron's price movement, emphasizing the impact of macroeconomic factors. Buy, Hold or Sell Regeneron Pharmaceuticals?

Comparing Regeneron Pharmaceuticals's Short Interest Against Its Peers Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing.

Furthermore, market volatility persisted as investor sentiment was hindered by geopolitical concerns and fluctuating policy expectations, influencing even robust companies such as Regeneron.

Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.

View the latest Regeneron Pharmaceuticals Inc. (REGN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Terence Flynn has given his Buy rating due to a combination of factors that indicate a strong potential for Regeneron’s growth and market position.